Full Text

Turn on search term navigation

© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Objective

Tertiary lymphoid structures (TLSs) are found in a variety of malignancies and affect the growth of tumors, but few studies have addressed their role in lung adenocarcinoma (LAC). We aimed to evaluate clinical features associated with TLSs in patients with LAC.

Methods and Materials

A collection of resected pulmonary nodules in patients with LAC was retrospectively analyzed. TLSs were quantified by their number per square millimeter tumor area (density) and by the degree of lymphocyte aggregation (maturity) in each case. The correlation between TLS density and maturity and clinical features was calculated.

Results

A total of 243 patients were selected, of whom 219 exhibited TLSs. The occurrence of TLSs was correlated with computed tomography (CT) features as follows: pure ground‐glass nodules (pGGNs) (n = 43) was associated with a lower occurrence rate than part‐solid nodules (PSNs) (n = 112) and solid nodules (SNs) were (n = 88) (p = 0.037). TLS density was correlated with age and CT features. Poisson regression showed higher TLS density in PSNs and SNs than in pGGNs (incidence rate ratio [IRR]: 3.137; 95% confidence interval [CI]: 1.35–7.27; p = 0.008 and IRR: 2.44; 95% CI: 1.02–5.85; p = 0.046, respectively). In addition, TLS density was higher in patients aged under 60 years than in those aged over 60 years (IRR: 0.605; 95% CI: 0.4–0.92; p = 0.018). The maturity of TLSs was higher in patients with higher tumor stages (p = 0.026).

Conclusions

We demonstrated distinct profiles of TLSs in early LAC and their correlations with CT features, age, and tumor stages, which could help understand tumor progression and management.

Details

Title
Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors
Author
Ren, Fangping 1 ; Xie, Mei 2 ; Gao, Jie 3 ; Wu, Chongchong 4 ; Xu, Yang 2 ; Zang, Xuelei 5 ; Ma, Xidong 2 ; Deng, Hui 1 ; Song, Jialin 6 ; Huang, Aiben 1 ; Pang, Li 1 ; Qian, Jin 1 ; Yu, Zhaofeng 7 ; Zhuang, Guanglei 8 ; Liu, Sanhong 9   VIAFID ORCID Logo  ; Pan, Lei 1 ; Xue, Xinying 1 

 Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China 
 Department of Respiratory and Critical Care, the Chinese PLA General Hospital, Beijing, P.R. China 
 Department of Pathology, the Chinese PLA General Hospital, Beijing, P.R. China 
 Department of Radiology, the Chinese PLA General Hospital, Beijing, P.R. China 
 Center of Clinical Laboratory Medicine, the first Medical Centre, Chinese PLA General Hospital, Beijing, P.R. China 
 Department of Respiratory Medicine, Weifang Medical university, Weifang, People’s Republic of China 
 School of Medicine, Peking University, Beijing, P.R. China 
 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China 
 Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, P.R. China 
Pages
2969-2977
Section
RESEARCH ARTICLES
Publication year
2022
Publication date
Aug 2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
20457634
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2699798673
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.